The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Kaiser Reef (ASX:KAU) has recently passed one big important milestone: The company’s now a gold producer. So what lies ahead? With gold prices where they are, the reasons this news is exciting investors are obvious. Kaiser’s one-year returns are up +100% year-on-year, and Kaiser’s only just getting started.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Tune in to hear more from the man in charge himself on what the next three months hold for Kaiser, and what the second half of the year will hold.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

kau by the numbers
More From The Market Online
US flag

Dateline Resources pops +40% on Trump gov’t move to greenlight REE and gold mining

An injunction on ASX-listed Dateline Resources’ (ASX:DTR) California-based Colosseum REE and gold project appears set to be lifted after
The ASX Today feature image with a blue Australia silhouette (STOCK) beside The Market Link column branding.

ASX Today: XJO has a good day ahead of RBA rate call; AU bond sell-off continues

While we’re set to get the RBA’s next rate decision tomorrow – which all big bank analysts think is going to be a
Aussie cash

Northern Star jumps +7% on confirmed takeover rumour from Gold Fields Ltd

ASX-listed Northern Star Resources (ASX:NST) has confirmed reports in Bloomberg that it’s received a 100% takeover offer from a

AFT Pharmaceuticals opens Japan opportunity for Maxigesic IV

AFT Pharmaceuticals (ASX: AFP) has secured an exclusive development, licensing and supply agreement for its Maxigesic® IV (also known as Combogesic® IV)